Both overall outcomes and propensity score matched outcomes were compared in patients undergoing either lobectomy or segmentectomy for clinical stage IA adenocarcinoma of the lung. In the overall cohort, 3-year recurrence-free and overall survival were similar between the groups. Among the matched patients, RFS (92.9% vs 90.9%) and OS (93.2% vs 95.7%) were also similar between the lobectomy and segementectomy groups at 3 years.
